Payment overview · 2025
General Payments
$186.78
10 reported records · 9 companies
Healthcare provider profile · identity verified
Andrzej Peter Torbus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, NJ · NPI 1699070441
Verified facts
What the public records show
CMS Open Payments records show Andrzej Peter Torbus, M.D. received $186.78 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.32 | 26.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.31 | 11.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.00 | 10.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.03 | 9.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.40 | 8.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.98 | 8.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.88 | 8.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.01 | 8.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.85 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.78 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.32 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 78 |
| Alprazolam | Alprazolam | 193 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 45 |
| Losartan Potassium | Losartan Potassium | 138 | 42 |
| Metformin Hcl | Metformin Hcl | 129 | 40 |
| Ozempic | Semaglutide | 120 | 22 |
| Omeprazole | Omeprazole | 111 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 31 |
| Clonazepam | Clonazepam | 95 | 14 |
| Gabapentin | Gabapentin | 95 | 22 |
| Ezetimibe | Ezetimibe | 94 | 33 |
| Meloxicam | Meloxicam | 85 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 35 |
| Lisinopril | Lisinopril | 80 | 26 |
| Famotidine | Famotidine | 79 | 41 |
| Simvastatin | Simvastatin | 79 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 47 |
| Mounjaro | Tirzepatide | 77 | 12 |
| Sertraline Hcl | Sertraline Hcl | 76 | 28 |
| Furosemide | Furosemide | 75 | 21 |
| Jardiance | Empagliflozin | 73 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 19 |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 17 |
| Allopurinol | Allopurinol | 53 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 48 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 14 |
| Metformin Hcl Er | Metformin Hcl | 42 | 15 |
| Eliquis | Apixaban | 40 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | 15 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Linzess | Linaclotide | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Prolia | Denosumab | 27 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 19 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Prednisone | Prednisone | 16 | 12 |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.78 · 10 records | Exact Sciences Corporation | Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Flector, Licart, MOUNJARO, NURTEC ODT, SHINGRIX, Tirosint, Wegovy, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error